B
Bull
Bull · 25%SLQT
$2.27
Precio del escenario
$0.520
-0.019 (-3.70%)Al cierre
Loading chart…
- High
- 0.556
- Open
- 0.531
- VWAP
- 0.53
- Vol
- 1.37M
- Mkt Cap
- 463.49M
- Low
- 0.513
- Amount
- 722.73K
- EV/EBITDA, TTM
- 3.73
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.
AI analysis of SelectQuote Inc (SLQT)
sellSelectQuote Inc (SLQT) is not a good buy right now due to significant recent losses and declining revenue. The current price is $0.52, which is a staggering 75.93% lower than one year ago. Additionally, the stock has a very low RSI of 18.14, indicating it is oversold, but this also suggests a lack of buying momentum. The forward P/E ratio is extremely high at 66.67, which reflects overvaluation concerns given the company's recent performance. The main risk is the reported revenue decline of 6.7% in Q4 FY2026, which could further impact investor confidence and stock performance.
Métricas de valoración
The current forward P/E ratio for SelectQuote Inc (SLQT) is 66.67, compared to its 5-year average forward P/E of 0.07.
Alphio AI Price Scenarios for SLQT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SLQT
Cronología de eventos
Noticias
9.508-25NewsfilterSelectQuote Reports Q4 FY2026 Earnings Highlights
- 9.508-11Newsfilter
SelectQuote to Release Q4 and Full Year 2026 Financial Results
7.006-09GlobenewswireSelectQuote Faces Shareholder Lawsuit Investigation
- 7.006-09Newsfilter
SelectQuote Executives Allegedly Breached Fiduciary Duties
2.005-29NASDAQ.COMSelectQuote Stock Shows Strong Momentum
SLQT FAQ — answered by Alphio AI
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).
SelectQuote Inc (SLQT) is not a good buy right now due to significant recent losses and declining revenue. The current price is $0.52, which is a staggering 75.93% lower than one year ago. Additionally, the stock has a very low RSI of 18.14, indicating it is oversold, but this also suggests a lack of buying momentum. The forward P/E ratio is extremely high at 66.67, which reflects overvaluation concerns given the company's recent performance. The main risk is the reported revenue decline of 6.7% in Q4 FY2026, which could further impact investor confidence and stock performance.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.